





<p>Karsten Nysom – Denmark</p>  <p><u>Supported by SIOP Europe</u></p>		<p>University Hospital Rigshospitalet Department of Paediatric Haematology & Oncology Copenhagen</p> <p>Denmark</p>
---	---	---

Since September 2012, I have been employed full time for setting up the first paediatric haematology and oncology phase 1 and 2 trial unit within the Nordic countries. Earlier this year, our unit became the first, and so far the only, Nordic member of the European network of paediatric haematology and oncology phase 1 and 2 trial units – the *Innovative Therapies for Children with Cancer (ITCC)* consortium. Wishing to contribute actively to the *Innovative Therapies in Children with Cancer (ITCC)* collaboration, and having coordinated the paediatric neuro-oncology team in Copenhagen for the previous 5 years, I applied for the course with a synopsis for a trial with a new combination treatment for *sonic hedgehog*-driven medulloblastomas.

I had the **privilege and the honour of being selected as one of workshop participants sponsored by SIOP Europe**. As described in the announcement of the workshop and by previous workshop participants, the six working days in Flims were very intense, but also very fruitful. As I had been warned about when I applied for the course, my protocol concept underwent major changes during the workshop – all for the better. My very best experience during the workshop was working very closely with the faculty, in particular my personal mentor, Dr. Birgit Geoerger who is part of the Flims faculty as well as chair of the clinical trials committee of ITCC. Another very fruitful experience was working, discussing, and socialising with the two other paediatric oncology colleagues participating in the course, Dr. Petra Temming from Essen and Dr. Pablo Berlanga Charriel from Valencia. Finally, the whole concept of the course, spending much of the course time in what is called the “protocol development group”, was very stimulating and illustrated the wide variety in clinical cancer trials. My own protocol development group included one other paediatric oncologist, two breast cancer specialists, one colleague from an adult oncology phase 1 trial unit, and three colleagues developing cancer surgery trials. Our group’s faculty consisted of a paediatric oncologist (BG), a biostatistician, a cancer surgery specialist, and a physician working in early drug development in the pharmaceutical industry. I look forward to developing my protocol further in an ongoing dialogue with the other members of ITCC and would like to thank SIOP Europe warmly for allowing me to get the unique experience of participating in the Flims workshop. It will certainly help me in further developing the paediatric haematology and oncology phase 1 and 2 trial unit at Rigshospitalet, Copenhagen, Denmark and thus help giving children from the Nordic countries access to the newest cancer treatments.